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Abstract
Objective: To determine the associations between individual metabolic syn-
drome (MetS) components and peripheral neuropathy in a large population-
based cohort from Pinggu, China. Methods: A cross-sectional, randomly
selected, population-based survey of participants from Pinggu, China was per-
formed. Metabolic phenotyping and neuropathy outcomes were performed by
trained personnel. Glycemic status was defined according to the American Dia-
betes Association criteria, and the MetS using modified consensus criteria (body
mass index instead of waist circumference). The primary peripheral neuropathy
outcome was the Michigan Neuropathy Screening Instrument (MNSI) examina-
tion. Secondary outcomes were the MNSI questionnaire and monofilament test-
ing. Multivariable models were used to assess for associations between
individual MetS components and peripheral neuropathy. Tree-based methods
were used to construct a classifier for peripheral neuropathy using demograph-
ics and MetS components. Results: The mean (SD) age of the 4002 participants
was 51.6 (11.8) and 51.0% were male; 37.2% of the population had normo-
glycemia, 44.0% prediabetes, and 18.9% diabetes. The prevalence of peripheral
neuropathy increased with worsening glycemic status (3.25% in normoglycemia,
6.29% in prediabetes, and 15.12% in diabetes, P < 0.0001). Diabetes (odds ratio
[OR] 2.60, 95% CI 1.77–3.80) and weight (OR 1.09, 95% CI 1.02–1.18) were
significantly associated with peripheral neuropathy. Age, diabetes, and weight
were the primary splitters in the classification tree for peripheral neuropathy.
Interpretation: Similar to previous studies, diabetes and obesity are the main
metabolic drivers of peripheral neuropathy. The consistency of these results
reinforces the urgent need for effective interventions that target these metabolic
factors to prevent and/or treat peripheral neuropathy.
Introduction
Peripheral neuropathy is a highly prevalent condition,
particularly in older populations.1–3 This disease affects
patients by causing pain, decreased quality of life, falls,
ulcerations, and amputations.3–5 Unfortunately, outside of
medications for neuropathic pain, few therapies exist to
help patients with peripheral neuropathy.4 Even in
patients with type 2 diabetes, glycemic control has only a
small effect on the prevention of peripheral neuropathy.6
Furthermore, a significant proportion of patients with
peripheral neuropathy have no known underlying cause.7–10
Therefore, a better understanding of the underlying causes
is needed to inform the development of new disease modi-
fying treatments.
Multiple studies have implicated the metabolic syn-
drome (MetS) as a potential cause of peripheral neuropa-
thy.11–14 However, studies that have investigated the
contributions of the individual components have revealed
mixed results.15–21 We have recently shown that diabetes,
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prediabetes, and obesity are the main metabolic compo-
nents associated with peripheral neuropathy in a United
States obese population.22 Similarly, in a United States
elderly population, we demonstrated that diabetes, obe-
sity, and the number of metabolic components are associ-
ated with peripheral neuropathy.23 Another group has
performed similar studies in Shanghai, China. They found
that patients with diabetes and prediabetes had a higher
prevalence of peripheral neuropathy compared to patients
with normoglycemia.24 Waist circumference and fasting
glucose were the main metabolic factors associated with
peripheral neuropathy. The same group observed that the
peripheral neuropathy prevalence increased as the number
of MetS components increased.25 However, the associa-
tion with MetS lost statistical significance when adjusted
for insulin resistance.
We aimed to determine the associations between indi-
vidual MetS components and peripheral neuropathy in a
large population-based cohort from Pinggu, China. In
contrast to the previous Chinese study in Shanghai, we
included a categorical classification of glycemic status,
included interaction terms, limited the analysis to meta-
bolic factors, and avoided potential collinearity in the
models. We also investigated the association between the
number of MetS components. Unlike the previous Chi-
nese study, we evaluated the number of MetS components
in addition to hyperglycemia and adjusted for the glyce-
mic effect in the models. Finally, we used a tree-based
approach to build a classifier for peripheral neuropathy
based on demographics and MetS components. The
resulting classification tree allowed identification and
characterization of peripheral neuropathy risk groups.
Material and Methods
Population
This study was part of the larger Pinggu metabolic disease
study. The study design was a cross-sectional, randomly
selected, population-based survey of participants from
Pinggu, China. Participants were obtained by a stratified,
random sampling method with 5-year age segments of
each gender. There are total of 16 towns in the rural area.
Five of these towns were randomly selected, and five vil-
lages were randomly selected from each town. A total of
2500 participants were randomly sampled from these 25
villages. The remaining 2500 participants were randomly
sampled from a randomly chosen urban district (one of
two). Individuals were required to be 25–74 years old,
born in Pinggu, and lived there for five or more years.
Pregnant women, individuals who for medical or other
reasons would not be able to return for repeat testing
over a 2–5-year period were excluded given the
longitudinal nature of the larger study. Sexually active
women were required to refrain from unprotected sexual
intercourse during the course of the study (3 weeks). All
study protocols were approved by the institutional review
board at the University of Michigan.
Metabolic syndrome components
Individuals filled out surveys including demographic
information, and all questions were posed in Chinese via
a trained interviewer who recorded responses into a
secure computer database. Study team members were pre-
sent to answer any questions posed by the participants
taking the survey. In addition, fasting laboratory assess-
ments were performed included a fasting (10–12 h) lipid
panel and oral glucose tolerance test (75 g of glucose).
Individuals were also measured by a technician for height
and weight. Blood pressure was measured in triplicate
with the participant’s feet flat on the ground.
Diabetes (fasting glucose ≥126 or 2 h glucose ≥200)
and prediabetes (fasting glucose ≥100 or 2 h glucose
≥140) were defined according to the American Diabetes
Association criteria.26 Consensus MetS criteria were used
to define the MetS and its individual components, with
the exception of body mass index (BMI) instead of waist
circumference as these data were not available.27 Specifi-
cally, the MetS criteria, in addition to the hyperglycemia
definition above, were a BMI ≥30, systolic blood pressure
(SBP) ≥130 or diastolic blood pressure ≥85, triglycerides
≥150 mg/dL, and high-density lipoprotein (HDL)
<40 mg/dL in men and <50 mg/dL in women.
Peripheral neuropathy
The Michigan Neuropathy Screening Instrument (MNSI)
examination and questionnaire were performed by trained
personnel as previously described.28 Monofilament testing
was performed with a Semmes Weinstein 5.07/10-g monofil-
ament on the dorsum of the dominant great toe. The pri-
mary peripheral neuropathy outcome was an abnormal
MNSI examination (≥2.5). Secondary peripheral neuropathy
outcomes included an abnormal MNSI questionnaire (≥4),
and an abnormal monofilament examination (participant is
unable to feel three or more applications out of 10).28
Statistical analysis
Descriptive statistics were used to describe the demo-
graphics and metabolic phenotype of the population. We
determined the prevalence of peripheral neuropathy (all
three definitions) stratified by glycemic status. We then
applied the Cochran-Armitage test to investigate for a
trend in the peripheral neuropathy prevalence in the three
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groups based on glycemic status. Similarly, we determined
the prevalence of peripheral neuropathy (primary out-
come) stratified by glycemic status and the number of
MetS components. We then used the Cochran-Armitage
test to determine whether there was a significant trend
between peripheral neuropathy and the number of MetS
components within each glycemic subgroup.
Multivariable logistic regression was used to model the
peripheral neuropathy outcomes as a function of the
MetS components (weight as a surrogate for waist cir-
cumference, hyperglycemia in the prediabetic range,
hyperglycemia in the diabetic range, HDL level, triglyc-
eride level, SBP), after adjusting for baseline demographic
factors (age, sex, height). Interaction effects between gly-
cemic status and the other four MetS components were
examined by adding them individually to the multivari-
able logistic regression models described above.
We performed tree-based analyses (statistical machine
learning) to construct a classifier for peripheral neuropa-
thy based on demographics (age, gender, and height) and
the MetS components. In the tree paradigm, the covariate
space is partitioned recursively in a binary fashion. Our
analyses began with the entire patient cohort and found
the best split into two groups based on a variable that
makes the resultant two groups most homogeneous within
themselves. For our binary outcome of peripheral neu-
ropathy, within group homogeneity was measured using
the Gini impurity. The two groups were again partitioned
(each group being split on the same or other variables),
thereby creating a tree structure. At each step, to select the
best split, the tree-growing paradigm examined every pos-
sible cut point for each predictor variable. This process
was continued until the groups reached a minimum size
(10 patients in each group). Because the resulting tree was
overgrown (thereby overfitting the data), a subtree was
chosen using cost-complexity pruning.29,30 The classifica-
tion tree was evaluated by examining the percent correct
classification (overall, as well as for the peripheral neu-
ropathy cases). We implemented inverse weighting within
our classification tree to give proportionally more weight
to correct classification of the neuropathy cases. The final
tree was selected using a 10-fold cross-validation
approach.29,30 All analyses were performed with SAS 9.3
(Cary, NC) or in R version 3.2.3 using the rpart package.
Results
Demographics and metabolic phenotyping are presented
in Table 1 for the 4002 participants. The mean (SD) age
was 51.6 (11.8) and 51.0% were male. Normoglycemic
participants accounted for 37.2% of the population, pre-
diabetes 44.0%, and diabetes 18.9%, which is comparable
to the distribution in a previous large Chinese cohort
study.24 The MetS was present in 38.0%. The mean (SD)
BMI was 26.1 (3.8), SBP 130.1 (18.1), triglycerides 141.2
(130.0), and HDL 45.0 (12.0).
The prevalence of peripheral neuropathy increased with
worsening glycemic status regardless of the peripheral neu-
ropathy definition used (P < 0.0001 for all three peripheral
neuropathy outcomes). The prevalence in those with predi-
abetes was higher than those with normoglycemia using
the MNSI examination and monofilament definitions
(P < 0.0001), but not using the MNSI questionnaire defini-
tion (P = 0.30). Using the MNSI examination, the preva-
lence was 3.25% in normoglycemic participants, 6.29% in
prediabetes, and 15.12% in diabetes. Using the MNSI ques-
tionnaire, the prevalence was 1.21% in normoglycemic par-
ticipants, 1.65% in prediabetes, and 6.08% in diabetes.
Table 1. Demographics of the Pinggu population stratified by glycemic status.
Variable Total Normoglycemia Prediabetes Diabetes
Subjects, N (%) 4002 (100%) 1487 (37.2%) 1758 (44.0%) 757 (18.9%)
Age, mean (SD) 51.6 (11.8) 47.2 (11.8) 53.2 (11.3) 56.7 (9.9)
Male, N (%) 2039 (51.0%) 885 (59.5%) 816 (46.4%) 338 (44.7%)
Height (cm), mean (SD) 162.6 (8.4) 162.3 (8.4) 162.7 (8.2) 162.9 (8.6)
Fasting glucose (mg/dL), mean (SD) 109.5 (29.4) 93.0 (4.8) 105.8 (7.5) 150.9 (46.0)
2 h glucose (mg/dL), mean (SD) 133.1 (46.4) 106.9 (19.0) 136.4 (8.2) 228.3 (64.7)
BMI (kg/m2), mean (SD) 26.1 (3.8) 24.9 (3.6) 26.5 (3.8) 27.4 (3.8)
SBP (mmHg), mean (SD) 130.1 (18.1) 123.6 (17.0) 132.5 (17.1) 137.5 (18.3)
DBP (mmHg), mean (SD) 78.7 (11.4) 75.8 (10.7) 80.2 (11.3) 81.1 (11.7)
Cholesterol (mg/dL), mean (SD) 190.6 (38.1) 183.0 (33.8) 193.7 (37.4) 198.2 (44.4)
Triglycerides (mg/dL), mean (SD) 141.2 (130.0) 106.3 (85.5) 150.7 (134.7) 187.8 (167.9)
HDL (mg/dL), mean (SD) 45.0 (12.0) 46.9 (12.2) 44.4 (11.8) 42.7 (11.6)
LDL (mg/dL), mean (SD) 111.3 (31.5) 107.2 (29.0) 114.0 (31.5) 112.9 (35.1)
Metabolic syndrome, N (%) 1519 (38.0%) 138 (9.3%) 900 (51.2%) 481 (63.5%)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; LDL, low-density
lipoprotein cholesterol.
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Using the monofilament definition, the prevalence was
3.70% in normoglycemic participants, 7.29% in predia-
betes, and 9.13% in diabetes. Controlling for glycemic sta-
tus, the prevalence of peripheral neuropathy increased with
the number of MetS components, particularly in those with
normoglycemia (P = 0.16) and prediabetes (P = 0.10), but
the result was not statistically significant (Fig. 1).
In a multivariable logistic regression model investigating
the individual MetS components, hyperglycemia in the dia-
betic range (odds ratio [OR] 2.60, 95% CI 1.77–3.80) and
weight (OR 1.09, 95% CI 1.02–1.18) were significantly
associated with the peripheral neuropathy primary out-
come (Table 2, MNSI examination). Age, gender, and
height were also significantly associated with peripheral
neuropathy. For MNSI questionnaire and monofilament,
hyperglycemia in the diabetic range was the only MetS
component associated with peripheral neuropathy (OR
3.85, 95% CI 2.09–7.09 and OR 1.51, 95% CI 1.01–2.25,
respectively). Age and gender were also significantly associ-
ated with peripheral neuropathy using these two defini-
tions. Of note, hyperglycemia in the prediabetic range had
an OR of 1.11–1.41 in the three models, but did not reach
statistical significance. No statistically significant interac-
tions between glycemic status and other MetS components
were observed. In a multivariable logistic regression model
investigating glycemic status and the number of additional
MetS components, the number of MetS components (OR
1.17, 95% CI 1.03–1.32) was significantly associated with
the peripheral neuropathy primary outcome. Diabetes (OR
2.71, 95% CI 1.86–3.94), but not prediabetes (OR 1.25,
95% CI 0.87–1.80), was also significantly associated with
peripheral neuropathy in this model.
Using tree analysis, we found that age, glycemic status,
and weight were the main demographic and metabolic
factors that could help discriminate peripheral neuropathy
status (Fig. 2). The resulting tree first separates the popu-
lation into three groups based on age. Patients aged less
than 52.5 years old were given a class prediction of “no
peripheral neuropathy,” with 97.9% accuracy. Peripheral
neuropathy was much more common in those greater
than or equal to 67.5 years old (93 out of 360, 25.8%).
Those older than 67.5 were predicted to have neuropathy
using this classification tree. In those between these two
age group, diabetes status, weight and SBP were used to
split patients into neuropathy groups. For patients aged
between 52.5 and 67.5, diabetes status increased the prob-
ability of peripheral neuropathy (339 out of 404, 83.9%).
Patients in this middle age group that did not have dia-
betes were further split based on weight and SBP to deter-
mine their final neuropathy classification.
Figure 1. The prevalence of distal symmetric polyneuropathy (DSP) with increasing metabolic syndrome components stratified by glycemic status.
DSP was defined as those with a Michigan Neuropathy Screening Instrument (MNSI) Examination score >2. Glycemic status was determined by
the glucose tolerance test according to the Expert Committee on the diagnosis and classification of diabetes mellitus. Metabolic syndrome
components were defined using modified consensus criteria.
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Discussion
In a large, population-based study in Pinggu, China, we
found that diabetes, weight, and the number of MetS
components in addition to hyperglycemia are associated
with peripheral neuropathy. Participants with prediabetes
also have a higher prevalence of peripheral neuropathy,
but the association does not meet statistical significance
in multivariable models. These results are comparable to
findings in other populations including those in the Uni-
ted States,22,23 another region in China,24,25 and the
Netherlands.31 Now that the evidence supporting these











Age 1.10 (1.09, 1.12)* 1.07 (1.05, 1.10)* 1.10 (1.08, 1.12)*
Male (reference female) 1.68 (1.14, 2.47)* 2.03 (1.05, 3.91)* 1.56 (1.05, 2.31)*
Height unit = 5 cm 1.20 (1.05, 1.37)* 0.89 (0.71, 1.10) 1.14 (1.00, 1.15)
MetS components
Diabetes 2.60 (1.77, 3.80)* 3.85 (2.09, 7.09)* 1.51 (1.01, 2.25)*
Prediabetes (reference normal) 1.21 (0.84, 1.75) 1.11 (0.60, 2.06) 1.41 (1.00, 1.99)
Weight unit = 5 kg 1.09 (1.02, 1.18)* 1.00 (0.98, 1.03) 1.00 (0.98, 1.01)
SBP unit = 10 mmHg 1.04 (0.96, 1.11) 0.93 (0.82, 1.05) 1.07 (0.99, 1.15)
Triglycerides unit = 50 mg/dL 1.01 (0.96, 1.06) 0.90 (0.79, 1.02) 0.94 (0.87, 1.01)
HDL unit = 10 mg/dL 0.99 (0.87, 1.12) 0.87 (0.69, 1.08) 1.03 (0.91, 1.16)
MetS, metabolic syndrome; MNSI, Michigan Neuropathy Screening Instrument; OR, odds ratio; SBP, systolic blood pressure; HDL, high-density
lipoprotein cholesterol.
*P < 0.05.
Figure 2. Classification tree analysis for peripheral neuropathy based on demographics and the MetS components. A tree-based approach was
used to build a classifier for peripheral neuropathy based on demographics and metabolic syndrome components. The resulting classification tree
allowed identification and characterization of peripheral neuropathy risk groups.
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specific metabolic drivers of nerve injury is increasingly
robust, efforts should turn to interventional studies aimed
at weight loss and/or exercise in populations at high risk
of peripheral neuropathy. In addition, using statistical
machine learning, we demonstrate that age, diabetes, and
weight are the key factors that can help clinicians target
specific populations for peripheral neuropathy screening.
Specifically, patients over the age of 67.5 (25.8%), those
over 52.5 with diabetes (83.9%), and those over 52.5 and
weighing over 60.75 kg (8.5%) are much more likely to
have peripheral neuropathy compared to those under the
age of 52.5 (2.1%).
While diabetes is the strongest and most well-established
metabolic driver of peripheral neuropathy, determining the
other metabolic contributors is critical to understand the
population at risk and to inform new interventions to pre-
vent and/or treat this common condition. Including this
study, five recent investigations reveal that obesity is signif-
icantly associated with peripheral neuropathy in multivari-
able analyses.22–24,31 Our results are comparable to those
found in 2035 Han Chinese subjects in Shanghai.24 Impor-
tantly, we were able to address important limitations of the
previous study including addressing the effects of interac-
tions between metabolic components and glycemic status,
focusing the analysis on metabolic factors, and avoiding
collinearity in the multivariable models. Our population
demographics were also different with our study including
younger participants (51.5 vs. 61.5), with a higher propor-
tion of normoglycemia (37.2% vs. 19.9%), a higher mean
BMI (26.1 vs. 24.4), and more males (51.0% vs. 43.3%).
Despite the differences in population location and demo-
graphics, the definition of neuropathy, and statistical mod-
eling design, the results are consistent. Similarly, studies in
obese and elderly populations in the United States,22,23 and
an older population in the Netherlands31 lead to the same
conclusion despite study design differences. With strong
evidence supporting obesity as a metabolic driver of
peripheral neuropathy, we need to start considering obesity
as a potential cause of peripheral neuropathy in the nondi-
abetic obese and design interventions that address this
underlying metabolic cause.
In contrast to the evidence supporting obesity, the data
supporting prediabetes is less clear. We found that the
prevalence of peripheral neuropathy was higher in those
with prediabetes than those with normoglycemia, but the
association was not significant in multivariable models.
With many previous studies supporting,16,32,33 and some
not supporting,23,34 an association of prediabetes with
peripheral neuropathy, our results do not push the overall
level of evidence much in either direction. Our study is
now the third to show an increased OR in those with pre-
diabetes that does not meet statistical significance.22,31
Possible explanations are that the study was not
adequately powered to detect this small effect size or that
prediabetes is not the underlying metabolic driver of
nerve injury when accounting for other metabolic factors.
Another possibility is that definitions of neuropathy that
primarily measure large fiber function, such as in our
study, may miss the association between prediabetes and
neuropathy because prediabetes may preferentially injure
small fiber nerves.35 Interestingly, the only other study
addressing this issue in a Chinese population demon-
strated that 2 h postprandial glucose levels were associ-
ated with peripheral neuropathy in the prediabetes
population.24 Regardless of whether prediabetes is one of
the underlying metabolic drivers of peripheral neuropa-
thy, the best interventions to study are unlikely to change.
Current data support weight loss and/or exercise as the
best treatment to prevent prediabetes from transitioning
to diabetes,36 and these are also the best interventions for
the now well-established metabolic driver of peripheral
neuropathy, obesity.
Besides diabetes and obesity, we also found that the
number of MetS components in addition to hyper-
glycemia was significantly associated with peripheral neu-
ropathy. This finding was observed although obesity was
the only other MetS component significantly associated
with peripheral neuropathy. Our finding is comparable to
studies performed in China,25 the United States,23 and
the Netherlands.31 Unlike the studies in China and
Netherlands, we did not include hyperglycemia as one of
the MetS components since this is already the strongest
and most well-established risk factor for peripheral neu-
ropathy. The study in United States used a similar model-
ing strategy with comparable results. Like some previous
studies, we did not find associations of peripheral neu-
ropathy with SBP, triglycerides, or HDL levels.22–24 There-
fore, our data would support interventions that target the
MetS as a whole rather than concentration on blood pres-
sure and/or cholesterol management. However, it should
be noted that some studies have revealed an association
with triglycerides and neuropathy.21,31
Another key finding is that we were able to use statisti-
cal machine learning to define the populations most at
risk of peripheral neuropathy including evaluating for
potential important interactions. This information is cru-
cial for physicians so that they can screen for peripheral
neuropathy in the appropriate groups. Emphasizing this
point, screening tests have the best performance in popu-
lations with a higher prevalence of disease. We found that
age alone is a key variable with participants over the age
of 67.5 at much higher risk of peripheral neuropathy than
those under 52.5 even with no other metabolic abnormali-
ties. Diabetes substantially increases the prevalence of
peripheral neuropathy in those over 52.5 to the point
where the vast majority of this population has highly
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morbid condition. Weight is another metabolic factor
identified, with those older than 52.5 and weighing more
than 60.75 kg having a slightly increased risk of peripheral
neuropathy. These data highlight the importance of age
and peripheral neuropathy. Previous studies have shown
that the prevalence of peripheral neuropathy, particularly
idiopathic peripheral neuropathy, rises dramatically with
age.37 Furthermore, these results reveal that diabetes has a
much greater impact on peripheral neuropathy than obe-
sity. Diabetes continues to be the strongest metabolic dri-
ver of peripheral neuropathy and new disease-modifying
treatments are desperately needed in this population.
Limitations include the cross-sectional study design
and lack of waist circumference, diabetes duration, and
medication data. Furthermore, the generalizability of
these results to other populations is unclear. However,
the population-based methodology and size of the popu-
lation are strengths. Furthermore, the consistency of
results with other investigations utilizing different popu-
lations and study designs support the data’s generaliz-
ability and validity. The neuropathy definition was based
on standardized examination and questionnaires, but not
on a neurologist’s history and examination or confirma-
tory measures (nerve conduction studies or skin biop-
sies). On the other hand, the MNSI questionnaire and
examination are validated measures of neuropathy and
have been used successfully in both type 1 and type 2
diabetic cohorts.28,38–40 While the MNSI instruments
have not been validated in Asian populations, the preva-
lence of neuropathy was comparable to a previous large
Chinese cohort study using a different neuropathy defi-
nition.24 We also were unable to adjust our models for
potential confounders such as alcohol consumption and
comorbidities.
A consensus is emerging that diabetes and obesity are
the main metabolic drivers of peripheral neuropathy. As a
result, intervention studies are needed to demonstrate
whether treatment of these underlying abnormalities can
lead to the prevention and/or treatment of this common
condition. Weight loss and/or exercise regimens may be
the most promising given that they can be effective in
those with diabetes, obesity, and prediabetes. Given the
lack of current disease modifying therapies, funding for
new treatments should be a priority.
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